Expert Review of Anti-infective Therapy最新文献_第2页

Nirmatrelvir/ritonavir: real world drug-drug interaction management experience. 尼马瑞韦/利托那韦：真实世界的药物相互作用管理经验。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-08-22 DOI: 10.1080/14787210.2024.2389884

Shahid Bukhari, Stephen Hughes, Nabeela Mughal, Luke S P Moore, Gary Davies, Adrian Vargas Zhang, Megan Ng, Zekiye Karagozlu, Marta Boffito

引用次数: 0

Emerging and alternative strategies for the treatment of nontuberculous mycobacterial infections. 治疗非结核分枝杆菌感染的新策略和替代策略。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-08-21 DOI: 10.1080/14787210.2024.2395003

Amritavarshini Sreekumar, Anil Kumar, Raja Biswas, Lalitha Biswas

{"title":"Emerging and alternative strategies for the treatment of nontuberculous mycobacterial infections.","authors":"Amritavarshini Sreekumar, Anil Kumar, Raja Biswas, Lalitha Biswas","doi":"10.1080/14787210.2024.2395003","DOIUrl":"10.1080/14787210.2024.2395003","url":null,"abstract":"Introduction: Nontuberculous mycobacteria (NTM) infections have emerged as a significant clinical challenge due to their intrinsic multidrug resistance and the limited efficacy of existing treatments. These infections are becoming increasingly prevalent, with a need for new and effective therapeutic strategies.Areas covered: This review addresses several key aspects of NTM infections: i) pathogenesis and epidemiology; ii) the limitations and challenges of current treatment options; iii) emerging and alternative therapeutic strategies; iv) advanced drug delivery systems such as nanoparticles and efflux pump inhibitors; v) innovative antibacterial alternatives like antimicrobial peptides, bacteriophage therapy, and phytochemicals; and vi) other potential treatment modalities such as inhaled nitric oxide, small molecules, surgical debridement, phototherapy, and immunomodulatory therapy.Expert opinion: Personalized medicine, advanced drug delivery systems, and alternative therapies hold promise for the future of NTM treatment. Early and accurate identification of NTM species, enabled by improved diagnostic methods, is critical for tailoring treatment regimens. Emerging therapies show promise against drug-resistant NTM strains, but overcoming barriers like clinical trials, regulatory hurdles, and high production costs is crucial. Continued research and innovation are essential to improve treatment efficacy and patient outcomes.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142003993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Artificial intelligence and prescription of antibiotic therapy: present and future. 人工智能与抗生素治疗处方：现在与未来。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-08-18 DOI: 10.1080/14787210.2024.2386669

Daniele Roberto Giacobbe, Cristina Marelli, Sabrina Guastavino, Alessio Signori, Sara Mora, Nicola Rosso, Cristina Campi, Michele Piana, Ylenia Murgia, Mauro Giacomini, Matteo Bassetti

{"title":"Artificial intelligence and prescription of antibiotic therapy: present and future.","authors":"Daniele Roberto Giacobbe, Cristina Marelli, Sabrina Guastavino, Alessio Signori, Sara Mora, Nicola Rosso, Cristina Campi, Michele Piana, Ylenia Murgia, Mauro Giacomini, Matteo Bassetti","doi":"10.1080/14787210.2024.2386669","DOIUrl":"https://doi.org/10.1080/14787210.2024.2386669","url":null,"abstract":"Introduction: In the past few years, the use of artificial intelligence in healthcare has grown exponentially. Prescription of antibiotics is not exempt from its rapid diffusion, and various machine learning (ML) techniques, from logistic regression to deep neural networks and large language models, have been explored in the literature to support decisions regarding antibiotic prescription.Areas covered: In this narrative review, we discuss promises and challenges of the application of ML-based clinical decision support systems (ML-CDSSs) for antibiotic prescription. A search was conducted in PubMed up to April 2024.Expert opinion: Prescribing antibiotics is a complex process involving various dynamic phases. In each of these phases, the support of ML-CDSSs has shown the potential, and also the actual ability in some studies, to favorably impacting relevant clinical outcomes. Nonetheless, before widely exploiting this massive potential, there are still crucial challenges ahead that are being intensively investigated, pertaining to the transparency of training data, the definition of the sufficient degree of prediction explanations when predictions are obtained through black box models, and the legal and ethical framework for decision responsibility whenever an antibiotic prescription is supported by ML-CDSSs.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141999667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antifungal resistance in dermatophytes - review of the epidemiology, diagnostic challenges and treatment strategies for managing Trichophyton indotineae infections. 皮癣菌的抗真菌耐药性--回顾流行病学、诊断挑战和处理 indotineae 毛癣菌感染的治疗策略。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-08-18 DOI: 10.1080/14787210.2024.2390629

Aditya K Gupta, Tong Wang, Avantika Mann, Shruthi Polla Ravi, Mesbah Talukder, Sara A Lincoln, Hui-Chen Foreman, Baruch Kaplan, Eran Galili, Vincent Piguet, Avner Shemer, Wayne L Bakotic

{"title":"Antifungal resistance in dermatophytes - review of the epidemiology, diagnostic challenges and treatment strategies for managing Trichophyton indotineae infections.","authors":"Aditya K Gupta, Tong Wang, Avantika Mann, Shruthi Polla Ravi, Mesbah Talukder, Sara A Lincoln, Hui-Chen Foreman, Baruch Kaplan, Eran Galili, Vincent Piguet, Avner Shemer, Wayne L Bakotic","doi":"10.1080/14787210.2024.2390629","DOIUrl":"10.1080/14787210.2024.2390629","url":null,"abstract":"Introduction: There is an increasing number of reports of Trichophyton indotineae infections. This species is usually poorly responsive to terbinafine.Areas covered: A literature search was conducted in May 2024. T.indotineae infections detected outside the Indian subcontinent are generally associated with international travel. Reports of local spread are mounting.As a newly identified dermatophyte species closely related to the T. mentagrophytes complex with limited genetic and phenotypic differences, there is an unmet need to develop molecular diagnosis for T. indotineae. Terbinafine has become less effective as a first-line agent attributed to mutations in the squalene epoxidase gene (Leu393Phe, Phe397Leu). Alternative therapies include itraconazole for a longer time-period or a higher dose (200 mg/day or higher). Generally, fluconazole and griseofulvin are not effective. In some cases, especially when the area of involvement is relatively small, topical non-allylamine antifungals may be an option either as monotherapy or in combination with oral therapy. In instances when the patient relapses after apparent clinical cure then itraconazole may be considered. Good antifungal stewardship should be considered at all times.Expert opinion: When both terbinafine and itraconazole are ineffective, options include off-label triazoles (voriconazole and posaconazole). We present four patients responding to these newer triazoles.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141901442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of truenat assays for the diagnosis of pulmonary and extrapulmonary tuberculosis: a systematic review and meta-analysis. 用于诊断肺部和肺部外结核病的真菌检测评估：系统综述和荟萃分析。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-08-11 DOI: 10.1080/14787210.2024.2389876

Shima Mahmoudi, Amir Hossein Sadegh Moghaddasi

{"title":"Evaluation of truenat assays for the diagnosis of pulmonary and extrapulmonary tuberculosis: a systematic review and meta-analysis.","authors":"Shima Mahmoudi, Amir Hossein Sadegh Moghaddasi","doi":"10.1080/14787210.2024.2389876","DOIUrl":"10.1080/14787210.2024.2389876","url":null,"abstract":"Background: Tuberculosis (TB) remains a significant global health concern, necessitating accurate and timely diagnostic methods. This study aimed to conduct a systematic review and meta-analysis to assess the diagnostic accuracy of Truenat assays for both pulmonary TB (PTB) and extrapulmonary TB (EPTB).Method: PubMed, Scopus, and Web of Science were systematically searched for studies comparing Truenat assays to Mycobacterium tuberculosis confirmation methods.Results: Comparing Truenat MTB assay with the Lowenstein-Jensen (LJ) culture, the pooled sensitivity and specificity were 86% (95% CI: 79-91%) and 86% (95% CI: 82-90%), respectively. For Mycobacterial Growth Indicator Tube (MGIT) culture comparison, pooled sensitivity was 88% (95% CI: 82-92%) with a specificity of 79% (95% CI: 57-92%). Compared to smear microscopy, Truenat assays displayed pooled sensitivity and specificity of 92% (95% CI: 78-98%) and 86% (95% CI: 64-95%). In comparison to Xpert MTB/RIF, Truenat assays exhibited a pooled sensitivity of 92% (95% CI: 80-97%) and a pooled specificity of 92% (95% CI: 56-99%) for PTB detection, and a pooled sensitivity of 94% (95% CI: 81-98%) and a specificity of 77% (95% CI: 32-96%) for the diagnosis of EPTB.Conclusion: This study underscores the potential of Truenat assays as valuable tools for diagnosing both PTB and EPTB.Prospero id: CRD42024526686.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141901467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The emergence of Japanese encephalitis as a public health concern in New South Wales Australia. 日本脑炎成为澳大利亚新南威尔士州的公共卫生问题。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-07-23 DOI: 10.1080/14787210.2024.2381824

Prakasini Satapathy, Sarvesh Rustagi, Israa Habeeb Naser, Shilpa Gaidhane, Quazi Syed Zahiruddin, Rachana Mehta, Vasso Apostolopoulos, Ranjit Sah

引用次数: 0

How is ceftobiprole used in Canada: the CLEAR study final results. 头孢替吡咯在加拿大的使用情况：CLEAR 研究的最终结果。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-07-15 DOI: 10.1080/14787210.2024.2374280

George G Zhanel, Justin Kosar, Melanie Baxter, Rita Dhami, Sergio Borgia, Neal Irfan, Gordon Dow, Maxime Dube, Teagen Rolf von den Baumen, Carlo Tascini, Anna Lee, Zain Chagla, Gabriel Girouard, Samuel Bourassa-Blanchette, May Wu, Yoav Keynan, Andrew Walkty, James A Karlowsky

{"title":"How is ceftobiprole used in Canada: the CLEAR study final results.","authors":"George G Zhanel, Justin Kosar, Melanie Baxter, Rita Dhami, Sergio Borgia, Neal Irfan, Gordon Dow, Maxime Dube, Teagen Rolf von den Baumen, Carlo Tascini, Anna Lee, Zain Chagla, Gabriel Girouard, Samuel Bourassa-Blanchette, May Wu, Yoav Keynan, Andrew Walkty, James A Karlowsky","doi":"10.1080/14787210.2024.2374280","DOIUrl":"10.1080/14787210.2024.2374280","url":null,"abstract":"Background: We report the final results of the clinical usage of ceftobiprole in patients in Canada from data in the national CLEAR (Canadian Le adership on Antimicrobial Real-Life Usage) registry.Research design and methods: The authors review the final data using the national ethics approved CLEAR study. Thereafter, the literature is surveyed regarding the usage of ceftobiprole to treat patients with infectious diseases via PubMed (up to March 2024).Results: In Canada, ceftobiprole is primarily used as directed therapy to treat a variety of severe infections caused by MRSA. It is primarily used in patients failing previous antimicrobials, is frequently added to daptomycin and/or vancomycin with high microbiological and clinical cure rates, along with an excellent safety profile. Several reports attest to the microbiological/clinical efficacy and safety of ceftobiprole. Ceftobiprole is also reported to be used empirically in select patients with community-acquired bacterial pneumonia (CABP), as well as hospital-acquired bacterial pneumonia (HABP).Conclusions: In Canada, ceftobiprole is used mostly as directed therapy to treat a variety of severe infections caused by MRSA, in patients failing previous antimicrobials. It is frequently added to, and thus used in combination with daptomycin and/or vancomycin with high microbiological/clinical cure rates, and an excellent safety profile.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141616137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tineas caused by hedgehogs due to Trichophyton erinacei an ascending agent of dermatophytosis. 刺猬因埃里纳西毛癣菌引起的尖锐湿疣，埃里纳西毛癣菌是一种皮肤癣菌病的上升型病原体。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-07-12 DOI: 10.1080/14787210.2024.2378980

Alexandro Bonifaz, Paola Lumbán-Ramírez, María Guadalupe Frías-de-León, Helena Vidaurri de la Cruz

引用次数: 0

Intranasal antivirals against respiratory syncytial virus: the current therapeutic development landscape. 针对呼吸道合胞病毒的鼻内抗病毒药物：当前的治疗开发前景。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-07-09 DOI: 10.1080/14787210.2024.2378185

Victor Baba Oti, Adi Idris, Nigel A J McMillan

{"title":"Intranasal antivirals against respiratory syncytial virus: the current therapeutic development landscape.","authors":"Victor Baba Oti, Adi Idris, Nigel A J McMillan","doi":"10.1080/14787210.2024.2378185","DOIUrl":"10.1080/14787210.2024.2378185","url":null,"abstract":"Introduction: Respiratory syncytial virus (RSV) causes bronchiolitis and other respiratory issues in immunocompromised individuals, the elderly, and children. After six decades of research, we have only recently seen the approval of two RSV vaccines, Arexvy and Abrysvo. Direct-acting antivirals against RSV have been more difficult to develop with ribavirin and palivizumab giving very modest reductions in hospitalizations and no differences in mortality. Recently, nirsevimab was licensed and has proven to be much more effective when given prophylactically. These are delivered intravenously (IV) and intramuscularly (IM), but an intranasal (IN) antiviral has several advantages in terms of ease of use, lower resource need, and acting at the site of infection.Areas covered: In this paper, we review the available literature on the current pre-clinical research landscape of anti-RSV therapeutics tested for IN delivery.Expert opinion: As RSV is a respiratory virus that infects both the upper and lower respiratory tracts, efforts are focused on developing a therapeutic that can be delivered via the nasal route. The rationale is to directly target the replicating virus with an obvious respiratory tract tropism. This approach will not only pave the way for a nasal delivery approach aimed at reducing respiratory viral illness but also controlling aerosol virus transmission.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141554456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Applications of β-defensins against infectious pathogenic microorganisms. 针对传染性病原微生物的β防御素应用。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-07-09 DOI: 10.1080/14787210.2024.2377677

Xiuyun Li, Xiaoming Wang, Jiajing Du, Xiangzhen Bu, Chao Peng, Ximeng Duan, Chen Fu

{"title":"Applications of β-defensins against infectious pathogenic microorganisms.","authors":"Xiuyun Li, Xiaoming Wang, Jiajing Du, Xiangzhen Bu, Chao Peng, Ximeng Duan, Chen Fu","doi":"10.1080/14787210.2024.2377677","DOIUrl":"10.1080/14787210.2024.2377677","url":null,"abstract":"Introduction: Antimicrobial peptides (AMPs) are polypeptides with potent antimicrobial activity against a broad range of pathogenic microorganisms. Unlike conventional antibiotics, AMPs have rapid bactericidal activity, a low capacity for inducing resistance, and compatibility with the host immune system. A large body of data supports the antimicrobial activities of a large body of data supports the antimicrobial activities of the class of AMPs known as β-defensins. This review provides a comprehensive analysis of the effects of β-defensins against various pathogenic microorganism: bacteria, fungi, viruses, Mycoplasmas and Chlamydiae. The primary mechanisms of β-defensins against pathogenic microorganisms include inhibition of biofilms formations, dissolution of membranes, disruption of cell walls, and inhibition of adhesion and receptor binding. Although further study and structural modifications are needed, β-defensins are promising candidates for antimicrobial therapy.Areas covered: This review describes the inhibitory effects of β-defensins on various pathogenic microorganisms. Additionally, we focus on elucidating the mechanisms underlying their actions to provide, providing valuable references for the further study of β-defensins.Expert opinion: The biological activities and modes of action of β-defensins provide powerful resources for clinical microbial infection management. Addressing the salt sensitivity and toxicity of β-defensins may further enhance their potential applications.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141544711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0